[{"id":"2278f5bb-b153-48d6-8bef-dfa2d6d4b72e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04535414","created_at":"2021-01-18T21:42:30.401Z","updated_at":"2024-07-02T16:34:58.809Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers","source_id_and_acronym":"NCT04535414","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 06/22/2023","start_date":" 06/22/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-05"},{"id":"d0a5b583-cfde-45fb-82fc-849fca7b6951","acronym":"","url":"https://clinicaltrials.gov/study/NCT00582257","created_at":"2021-01-18T02:08:30.161Z","updated_at":"2024-07-02T16:35:24.446Z","phase":"","brief_title":"Early Onset and Familial Gastric Cancer Registry","source_id_and_acronym":"NCT00582257","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 971","initiation":"Initiation: 12/01/2005","start_date":" 12/01/2005","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-05"},{"id":"bd544bf4-745a-4b82-abc5-b542c9fc7a34","acronym":"ROLo","url":"https://clinicaltrials.gov/study/NCT03620643","created_at":"2021-01-18T17:47:27.839Z","updated_at":"2024-07-02T16:35:25.368Z","phase":"Phase 2","brief_title":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","source_id_and_acronym":"NCT03620643 - ROLo","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • CDH1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • CDH1 mutation • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-12-22"},{"id":"e0ff64e5-f5f3-48fe-8823-ec69c14bf5dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04206891","created_at":"2021-01-18T20:29:28.352Z","updated_at":"2024-07-02T16:35:36.326Z","phase":"","brief_title":"CDH1 Germline Mutations in Lobular Breast Cancer","source_id_and_acronym":"NCT04206891","lead_sponsor":"European Institute of Oncology","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 421","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-09-21"},{"id":"513233c3-4e61-45fc-aea5-4e9b44e4a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01514045","created_at":"2021-01-18T06:21:47.928Z","updated_at":"2024-07-02T16:35:54.729Z","phase":"","brief_title":"The Gastric Cancer Foundation: A Gastric Cancer Registry","source_id_and_acronym":"NCT01514045","lead_sponsor":"Stanford University","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-02-24"},{"id":"20481648-b24a-4001-9d26-bf1b3e73c61c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451553","created_at":"2021-01-18T11:45:16.896Z","updated_at":"2024-07-02T16:36:09.285Z","phase":"Phase 1","brief_title":"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer","source_id_and_acronym":"NCT02451553","lead_sponsor":"University of Washington","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 04/16/2022","primary_completion_date":" 04/16/2022","study_txt":" Completion: 04/16/2022","study_completion_date":" 04/16/2022","last_update_posted":"2022-06-07"},{"id":"5c968a7c-8d14-474d-9a31-19f9508b0545","acronym":"","url":"https://clinicaltrials.gov/study/NCT03648879","created_at":"2021-03-25T15:53:02.111Z","updated_at":"2024-07-02T16:36:28.088Z","phase":"Phase 2","brief_title":"Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome","source_id_and_acronym":"NCT03648879","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA2 • CDH1 • CDH2 • CTNNA1","pipe":" | ","alterations":" PALB2 mutation • CDH1 mutation","tags":["BRCA2 • CDH1 • CDH2 • CTNNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • CDH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 02/11/2019","start_date":" 02/11/2019","primary_txt":" Primary completion: 04/20/2020","primary_completion_date":" 04/20/2020","study_txt":" Completion: 05/05/2020","study_completion_date":" 05/05/2020","last_update_posted":"2021-07-12"},{"id":"9ca7500b-db76-4432-92e2-c1439b920f0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01662739","created_at":"2021-01-18T07:11:00.732Z","updated_at":"2024-07-02T16:37:24.691Z","phase":"","brief_title":"Cremona Population-Based Gastric Tumors Registry","source_id_and_acronym":"NCT01662739","lead_sponsor":"Medicina e Arte Onlus","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 1000","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-03-06"}]